Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
156
archived clinical trials in
ALS

A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
UTHSCSA - First Outpatient Research Unit
mi
from
San Antonio, TX
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
UTHSCSA - First Outpatient Research Unit
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
The University of California Irvine
mi
from
Orange, CA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
St. Louis University, Department of Neurology & Psychiatry
mi
from
Saint Louis, MO
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
St. Louis University, Department of Neurology & Psychiatry
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Department of Neurology, Wake Forest School of Medicine
mi
from
Winston-Salem, NC
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Department of Neurology, Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center - Clinical Research Center
mi
from
Nashville, TN
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center - Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
UZ Leuven
mi
from
Leuven,
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
UZ Leuven
mi
from
Leuven,
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
The George Washington University Medical Center
mi
from
Washington,
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
The George Washington University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Avera Medical Group Neurology Sioux Falls
mi
from
Sioux Falls, SD
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Avera Medical Group Neurology Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment.
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment.
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Holy Cross Neuroscience Research Institute
mi
from
Fort Lauderdale, FL
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Holy Cross Neuroscience Research Institute
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Somnos/Neurology Associates Clinical Research
mi
from
Lincoln, NE
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Somnos/Neurology Associates Clinical Research
mi
from
Lincoln, NE
Click here to add this to my saved trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neurosciences Institute: Neurology - Charlotte
mi
from
Charlotte, NC
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neurosciences Institute: Neurology - Charlotte
mi
from
Charlotte, NC
Click here to add this to my saved trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Wesley Neurology Clinic
mi
from
Cordova, TN
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Wesley Neurology Clinic
mi
from
Cordova, TN
Click here to add this to my saved trials
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)
Tracking Brain Changes During Real and Imagined Movements in People With ALS (Lou Gehrig's Disease) and Healthy Volunteers.
Status: Enrolling
Updated:  5/26/2009
University of Michigan, Functional MRI Laboratory
mi
from
Ann Arbor, MI
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)
Tracking Brain Changes During Real and Imagined Movements in People With ALS (Lou Gehrig's Disease) and Healthy Volunteers.
Status: Enrolling
Updated: 5/26/2009
University of Michigan, Functional MRI Laboratory
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated:  5/13/2011
Georgia Institute of Technology
mi
from
Atlanta, GA
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated: 5/13/2011
Georgia Institute of Technology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated:  5/13/2011
Shepherd Center
mi
from
Atlanta, GA
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated: 5/13/2011
Shepherd Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated:  5/13/2011
Northwestern University
mi
from
Chicago, IL
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated: 5/13/2011
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated:  5/13/2011
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders
Status: Enrolling
Updated: 5/13/2011
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
PRISM Registry: Pseudobulbar Affect Registry Series
PRISM Registry: Pseudobulbar Affect Registry Series
Status: Enrolling
Updated:  6/2/2011
Avanir Pharmaceuticals
mi
from
Aliso Viejo, CA
PRISM Registry: Pseudobulbar Affect Registry Series
PRISM Registry: Pseudobulbar Affect Registry Series
Status: Enrolling
Updated: 6/2/2011
Avanir Pharmaceuticals
mi
from
Aliso Viejo, CA
Click here to add this to my saved trials
Coping Effectiveness Training for ALS
Coping Effectiveness Training for Recently Diagnosed ALS Patients and Care Partners
Status: Enrolling
Updated:  4/26/2012
New York State Psychiatric Institute at Columbia University Medical Center
mi
from
New York, NY
Coping Effectiveness Training for ALS
Coping Effectiveness Training for Recently Diagnosed ALS Patients and Care Partners
Status: Enrolling
Updated: 4/26/2012
New York State Psychiatric Institute at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated:  3/3/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated: 3/3/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
Status: Enrolling
Updated:  7/21/2015
Convergence Medical Devices
mi
from
Boston, MA
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
Status: Enrolling
Updated: 7/21/2015
Convergence Medical Devices
mi
from
Boston, MA
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)
Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)
Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis
Ascertainment of Death in ALS Patients
Status: Enrolling
Updated:  9/26/2015
NIEHS, Research Triangle Park
mi
from
Research Triangle Park, NC
Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis
Ascertainment of Death in ALS Patients
Status: Enrolling
Updated: 9/26/2015
NIEHS, Research Triangle Park
mi
from
Research Triangle Park, NC
Click here to add this to my saved trials
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]
Status: Enrolling
Updated:  10/1/2015
University of Wisconsin
mi
from
Madison, WI
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]
Status: Enrolling
Updated: 10/1/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Optimizing NIPPV Use for Patients With ALS
Effectiveness Trial of Detailed NIPPV Feedback to Patients
Status: Enrolling
Updated:  1/5/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Optimizing NIPPV Use for Patients With ALS
Effectiveness Trial of Detailed NIPPV Feedback to Patients
Status: Enrolling
Updated: 1/5/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated:  3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated: 3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated:  4/12/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated: 4/12/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated:  4/12/2016
California Pacific Medical Center -- Forbes Norris MDA/ALS Research Center
mi
from
San Francisco, CA
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated: 4/12/2016
California Pacific Medical Center -- Forbes Norris MDA/ALS Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated:  4/12/2016
University of Colorado at Denver
mi
from
Denver, CO
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated: 4/12/2016
University of Colorado at Denver
mi
from
Denver, CO
Click here to add this to my saved trials
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated:  4/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated: 4/12/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated:  4/12/2016
Northwestern University
mi
from
Chicago, IL
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
Status: Enrolling
Updated: 4/12/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials